Detailed description page of ThPDB2
This page displays user query in tabular form. |
Th1697 details |
Primary information | |
---|---|
ID | 16184 |
Therapeutic ID | Th1697 |
Protein Name | MVA3000 |
Sequence | NA |
Molecular Weight | NA |
Chemical Formula | NA |
Isoelectric Point | NA |
Hydrophobicity | NA |
Melting point | NA |
Half-life | NA |
Description | MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema. |
Indication/Disease | Investigated for use/treatment in viral infection. |
Pharmacodynamics | NA |
Mechanism of Action | NA |
Toxicity | NA |
Metabolism | NA |
Absorption | NA |
NA | |
Clearance | NA |
Categories | NA |
Patents Number | NA |
Date of Issue | NA |
Date of Expiry | NA |
Drug Interaction | NA |
Target | NA |
Brand Name | NA |
Company | NA |
Brand Description | NA |
Prescribed For | NA |
Chemical Name | NA |
Formulation | NA |
Physical Appearance | NA |
Route of Administration | NA |
Recommended Dosage | NA |
Contraindication | NA |
Side Effects | NA |
Useful Link 1 | Link |
Useful Link 2 | NA |
Remarks | NA |